Sponsors of nine new drugs, including Daiichi Sankyo for its anticancer medicine, quizartinib, Janssen for its anti-depressant, esketamine, and AbbVie for its rheumatoid arthritis treatment, upadacitinib, are set to learn whether their products are on track to secure a pan-EU approval.
Marketing authorization applications (MAAs) for the products are up for an opinion this week by the European Medicines Agency’s drug...








